Oral fusidic acid for the treatment of mild‐to‐moderate hidradenitis suppurativa

Documenti analoghi

• Secukinumab in bio‐experienced patients with moderate‐to‐severe hidradenitis suppurativa from a single center: an observational retrospective study
  di: Thuy M. Tran, et al.
  Pubblicazione: (2024)
• Demographics and treatment trends in the largest cohort of patients with Down syndrome and hidradenitis suppurativa
  di: Diem‐Phuong D. Dao, et al.
  Pubblicazione: (2024)
• Cardiovascular disease and hidradenitis suppurativa: inflammation beyond the skin
  di: Alejandro Molina‐Leyva
  Pubblicazione: (2024)
• Risk of respiratory diseases among hospitalized patients with hidradenitis suppurativa
  di: Nouf Almuhanna, et al.
  Pubblicazione: (2024)
• Vitamin D deficiency as a predictor of hidradenitis suppurativa severity
  di: Dimitra Koumaki, et al.
  Pubblicazione: (2024)